We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Integrated DNA Technologies Acquires Synthegen

Integrated DNA Technologies Acquires Synthegen

Integrated DNA Technologies Acquires Synthegen

Integrated DNA Technologies Acquires Synthegen

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Integrated DNA Technologies Acquires Synthegen"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Integrated DNA Technologies (IDT) has announced the completion of its acquisition of Houston, TX based custom oligonucleotide supplier Synthegen, Inc.

Illustrating its commitment to continued growth, this latest acquisition by Coralville, Iowa based IDT further expands the company’s expertise in the synthesis of modified oligonucleotides.

The acquisition of Synthegen follows IDT’s recent purchase of San Diego, CA based GenBase, Inc. and the opening of the company’s first satellite production center.

"Synthegen has developed significant skills and abilities that target the specialty oligo market," said Integrated DNA Technologies, Inc. COO Trey Martin.

"This acquisition allows us to merge that expertise with IDT’s industry-leading quality and QC systems."

"It also brings the Synthegen product range to a wider market, and ensures that our customers continue to benefit from the widest selection, highest service level, and most reliable and consistent delivery of custom oligos available anywhere."

"Our success over the last 10 years clearly played a central role in the development of this deal," said David Colvin, president of Synthegen.

"And as our customer segment is smaller and more specialized than IDT’s, we were delighted to discover that they share our belief that the customer is the most important part of what we do."

"We know that the needs of our clients will be well served, and that this deal will deliver significant benefits for them."

Colvin is working with Integrated DNA Technologies, Inc. to support the seamless transition of the Synthegen product line into IDT’s portfolio.